1 INDICATIONS AND USAGE
1.1 Acute Bacterial Exacerbation of Chronic Bronchitis
Clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to
Haemophilus influenzae,
Haemophilus parainfluenzae,
Moraxella catarrhalis, or
Streptococcus pneumoniae.
1.2 Acute Maxillary Sinusitis
Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to
Haemophilus influenzae,
Moraxella catarrhalis, or
Streptococcus pneumoniae.
1.3 Community-Acquired Pneumonia
Clarithromycin tablets are indicatedfor the treatment of mild to moderate infections caused by susceptible isolates due to:
Haemophilus influenzae (in adults)
Mycoplasma pneumoniae,
Streptococcus pneumoniae,
Chlamydophila pneumoniae (clarithromycin tablets [in adults and pediatric patients])
1.4 Pharyngitis/Tonsillitis
Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to
Streptococcus pyogenes as an alternative in individuals who cannot use first line therapy.
1.5 Uncomplicated Skin and Skin Structure Infections
Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to
Staphylococcus aureus, or
Streptococcus pyogenes.
1.6 Acute Otitis Media
Clarithromycin tablets are indicated in pediatric patients for the treatment of mild to moderate infections caused by susceptible isolates due to
Haemophilus influenzae,
Moraxella catarrhalis, or
Streptococcus pneumoniae [see
Clinical Studies (14.2)]
.
1.7 Treatment and Prophylaxis of Disseminated Mycobacterial Infections
Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to
Mycobacterium avium or
Mycobacterium intracellulare in patients with advanced HIV infection
[see
Clinical Studies (14.1)]
.
1.8
Helicobacter pylori Infection and Duodenal Ulcer Disease
Clarithromycin tablets are given in combination with other drugs in adults as described below to eradicate
H. pylori. The eradication of
H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence
[see
Clinical Studies (14.3)]
.
Clarithromycin tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with
H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate
H. pylori.
Clarithromycin tablets in combination with PRILOSEC (omeprazole) capsules are indicated for the treatment of patients with an active duodenal ulcer associated with
H. pylori infection. Regimens which contain clarithromycin tablets as the single antibacterial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting.
1.10 Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.